The startup develops a urine DNA test that measures epigenetic biomarkers to detect aggressive prostate cancer early and assess prognosis. This test generates a score indicating the likelihood of aggressive disease, helping medical professionals make informed decisions and potentially avoid unnecessary treatments.
Funding
$10K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for detecting aggressive prostate cancer often involve invasive procedures and may not accurately predict disease progression. This can lead to overtreatment of indolent cases and delayed intervention for aggressive forms of the disease.
Solution
The startup offers a urine-based DNA test that analyzes epigenetic biomarkers to identify aggressive prostate cancer early and assess a patient's prognosis. By measuring specific epigenetic markers in urine samples, the test generates a risk score that indicates the likelihood of aggressive disease development. This score assists medical professionals in making more informed treatment decisions, potentially reducing the need for unnecessary biopsies and treatments for patients with low-risk disease. The test aims to provide a non-invasive and accurate method for differentiating between aggressive and indolent prostate cancer, leading to more personalized and effective patient care.
Target Audience
The primary target audience includes urologists, oncologists, and other medical professionals involved in the diagnosis and management of prostate cancer, as well as men at risk of or diagnosed with prostate cancer.
Features
- Non-invasive urine sample collection
- Analysis of DNA methylation patterns associated with prostate cancer aggressiveness
- Proprietary algorithm for generating a risk score based on epigenetic biomarkers
- Clear and concise report indicating the likelihood of aggressive disease